Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02893826Phase 1Terminated

Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH

Role: lead

NCT02790632Phase 3Terminated

Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

Role: lead

NCT01893190Phase 1Completed

Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

Role: lead

All 3 trials loaded